Old Web
English
Sign In
Acemap
>
authorDetail
>
Gino Van Dooren
Gino Van Dooren
Janssen Pharmaceutica
Hepatitis C virus
Simeprevir
Viral load
Medicine
Hepatitis C
2
Papers
9
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.
2017
PLOS ONE
Tarik Asselah
Christophe Moreno
Christoph Sarrazin
M Gschwantler
Graham R. Foster
Antonio Craxì
Peter Buggisch
Faisal M. Sanai
Ceyhun Bicer
Oliver Lenz
Gino Van Dooren
Catherine Nalpas
I. Lonjon-Domanec
Michael Schlag
M. Buti
Show All
Source
Cite
Save
Citations (6)
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).
2016
PLOS ONE
Tarik Asselah
Christophe Moreno
Christoph Sarrazin
M Gschwantler
Graham R. Foster
Antonio Craxì
Peter Buggisch
Robert Ryan
Oliver Lenz
Jane Scott
Gino Van Dooren
I. Lonjon-Domanec
Michael Schlag
M. Buti
Show All
Source
Cite
Save
Citations (3)
1